The antimalarial drug atovaquone binds to saposin B with comparable affinity to coenzyme Q10

B. P. Huta, A. M. Roberts, E. S. Waters, V. Y. Yu, R. P. Doyle, M. R. Mehlenbacher, F. Bou-Abdallah

Research output: Contribution to journalArticle

3 Scopus citations

Abstract

Atovaquone is a front-line antimalarial drug that functions by competitively inhibiting binding of coenzyme Q10 to the cytochrome bc 1 complex. Atovaquone is administered orally, but has low solubility and is poorly absorbed with high variability in bioavailability. In vivo binding of human serum albumin has been cited as the major transporter of atovaquone in plasma. The research presented herein demonstrates that saposin B, a known binder/transporter of coenzyme Q10, also binds to atovaquone in a 1:1 ratio and with comparably high affinity at pH 5.5.

Original languageEnglish (US)
Pages (from-to)787-791
Number of pages5
JournalMedChemComm
Volume5
Issue number6
DOIs
StatePublished - Jun 2014

ASJC Scopus subject areas

  • Biochemistry
  • Molecular Medicine
  • Pharmacology
  • Pharmaceutical Science
  • Drug Discovery
  • Organic Chemistry

Fingerprint Dive into the research topics of 'The antimalarial drug atovaquone binds to saposin B with comparable affinity to coenzyme Q10'. Together they form a unique fingerprint.

  • Cite this

    Huta, B. P., Roberts, A. M., Waters, E. S., Yu, V. Y., Doyle, R. P., Mehlenbacher, M. R., & Bou-Abdallah, F. (2014). The antimalarial drug atovaquone binds to saposin B with comparable affinity to coenzyme Q10. MedChemComm, 5(6), 787-791. https://doi.org/10.1039/c3md00373f